These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23593719)

  • 21. Outcome results renew debate about diabetes drug development.
    Mullard A
    Lancet Diabetes Endocrinol; 2013 Nov; 1(3):179-80. PubMed ID: 24622363
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA committee urges tight restrictions on rosiglitazone.
    Roehr B
    BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA puts restrictions on use of controversial diabetes drug.
    Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
    [No Abstract]   [Full Text] [Related]  

  • 24. Alogliptin-induced bullous pemphigoid.
    Zafar M; Shahbaz M; Hawley I; Rahmani MJ
    Br J Hosp Med (Lond); 2020 Jul; 81(7):1-3. PubMed ID: 32730152
    [No Abstract]   [Full Text] [Related]  

  • 25. Assessing the cardiovascular safety of diabetes therapies.
    Goldfine AB
    N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
    [No Abstract]   [Full Text] [Related]  

  • 26. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
    Rosen CJ
    N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
    [No Abstract]   [Full Text] [Related]  

  • 27. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure.
    Asakawa T; Moritoh Y; Kataoka O; Suzuki N; Takeuchi K; Odaka H
    Life Sci; 2009 Jul; 85(3-4):122-6. PubMed ID: 19427871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric drug development programs for type 2 diabetes: A review.
    Christensen ML; Franklin BE; Momper JD; Reed MD
    J Clin Pharmacol; 2015 Jul; 55(7):731-8. PubMed ID: 25781151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The EXAMINE study].
    Violini R; Vigili de Kreutzenberg S
    G Ital Cardiol (Rome); 2014 Jun; 15(6):340-4. PubMed ID: 25072418
    [No Abstract]   [Full Text] [Related]  

  • 30. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
    Gorman C
    Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
    [No Abstract]   [Full Text] [Related]  

  • 31. [Prandial glucose regulator for type 2 diabetic patients. Beta cells produce insulin according to need].
    MMW Fortschr Med; 1999 Sep; 141(36):61. PubMed ID: 10904606
    [No Abstract]   [Full Text] [Related]  

  • 32. Trelagliptin: First Global Approval.
    McKeage K
    Drugs; 2015 Jul; 75(10):1161-4. PubMed ID: 26115728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosiglitazone: a case of regulatory hubris.
    Nissen SE
    BMJ; 2013 Dec; 347():f7428. PubMed ID: 24335808
    [No Abstract]   [Full Text] [Related]  

  • 34. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.
    Argyrakopoulou G; Doupis J
    Adv Ther; 2009 Mar; 26(3):272-80. PubMed ID: 19259628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
    Parks M; Rosebraugh C
    N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA approves pioglitazone for diabetes.
    Miller JL
    Am J Health Syst Pharm; 1999 Sep; 56(17):1698. PubMed ID: 10512494
    [No Abstract]   [Full Text] [Related]  

  • 38. Canagliflozin: a new drug for type 2.
    Goldman-Levine J
    Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
    [No Abstract]   [Full Text] [Related]  

  • 39. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
    Lotz N
    MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
    N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.